Is Kretto Syscon overvalued or undervalued?

As of 17 November 2025, Kretto Syscon's valuation grade has moved from fair to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued at this stage, with a PE ratio of 36.50, an EV to EBITDA ratio of 67.92, and a ROE of only 2.84%. These ratios suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.
In comparison to its peers, Kretto Syscon's PE ratio is notably lower than that of Max Healthcare, which stands at 77.22, and Fortis Healthcare at 70.78, both of which are also classified as very expensive. However, Apollo Hospitals, rated as attractive, has a PE of 64.41, indicating that Kretto Syscon's valuation may not be justified given its financial performance. Additionally, Kretto Syscon has underperformed the Sensex significantly over the past year, with a stock return of -30.67% compared to the Sensex's 9.50%, further reinforcing the notion that the stock is currently overvalued.